EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Transcutaneous auricular vagus nerve stimulation for the treatment of primary dysmenorrhea: A pilot study

Chenxi Wang, Wenjie Su, Xinyue Feng, Xingang Qi, Zilong Hong, Wanghuan Dun, Ming Zhang, Jixin Liu

Brain Stimulation · 2023

DOI: 10.1016/j.brs.2023.04.010 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Brain Stimulation, 2023. Verfasst von Chenxi Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Brain Imaging, School of Life Science and Technology, Xidian University, Xi'an, 710126, PR China; Engineering Research Center of Molecular…. Hauptthemen laut MEDLINE: Vagus Nerve Stimulation, Transcutaneous Electric Nerve Stimulation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary dysmenorrhea (PDM), characterized by lower abdominal pain, is a common gynecological disorder with a prevalence of up to 90% [1]. PDM can significantly reduce quality of life and induce poorer mood and hyperalgesia, which may increase susceptibility to other chronic pain conditions. However, dysmenorrhea is frequently poorly treated and even disregarded by the women themselves. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive technique that can deliver analgesic effects by electrically stimulating the auricular branch of the vagus nerve that innervates the cymba concha in the ear [2,3]. Many studies have provided evidence of anti-nociceptive effects in several chronic pain conditions, including pelvic pain and irritable bowel syndrome [3,4]. Menstrual pain associated with PDM is caused by an increased uterine contractility [5]. Stimulation of the vagus nerve could induce a parasympathetic nervous system response, which in turn may induce vasodilation in the pelvic organs, thereby reducing pain caused by ischemia [6]. Considering the uterus receives vagal innervation [7], taVNS is of interest as a potential therapeutic intervention for PDM. Here, we performed a single-blind, sham-controlled experimental design to investigate the effects of taVNS on PDM. Ten consecutive days of 1Hz taVNS (Rishena Medical Co., Ltd) were performed at the cymba conchae of the left ear, beginning 1–2 days after the end of menstruation. The Cox Menstrual Symptom Scale (CMSS), which consists of 17 items, was collected to evaluate the duration and severity of dysmenorrhea symptoms. CMSS scores were recorded at the end of each menstrual period in two pre-treatment and two post-treatment menstrual periods (Fig. 1A). The average of the CMSS scores for the two menstrual periods pre-treatment constituted the baseline data. The pre-treatment and post-treatment CMSS scores were compared. In addition, painrelated self-report questionnaires were collected, including the Fear of Pain Questionnaire (FPQ), the Pain Anxiety Symptom Scale (PASS), and the Pain Catastrophizing Scale (PCS). We studied the relationships between the efficacy of taVNS treatment in women with PDM and their pain-related self-report questionnaires. All participants were provided with information about the stimulation procedure, and wrote the informed consents. The research was conducted according to the Declaration of Helsinki and was approved by the local ethics committee. PDM women with a regular menstrual cycle were recruited according to the American College of Obstetricians and Gynecologists. Sixty PDM women with a mean age of 22.6 ± 2.3 years and a mean dysmenorrhea duration of 8.3 ± 1.4 years were recruited. All participants were randomly assigned to real (n = 30) or sham (n = 30) taVNS groups and were provided comprehensive training with the device. They were instructed to use the device for 30 minutes per day for 10 consecutive days (Fig. 1A). The duration of the taVNS session was the same for the real and sham taVNS. However, the stimulation lasted for 30 minutes in the real taVNS, whereas the stimulation lasted for 45 s in the sham taVNS. The taVNS was set to a frequency of 1 Hz with individual pulse widths of 200 μs, and pulse amplitude intensity was adjusted based on the participant’s tolerance [8]. In our results, we found that only real taVNS stimulation significantly improved dysmenorrhea symptoms in women with PDM (Fig. 1B). Specifically, the mean post-treatment CMSS score was significantly lower than the pre-treatment score (t = 5.98, p 0.05). No adverse reactions were found in the real and sham taVNS groups. Many studies have found that taVNS has promising analgesic effects on different somatosensory modalities in healthy people, such as reducing pain ratings in response to tonic heat pain, reducing sensitivity to mechanical pain, and raising mechanical and pressure pain thresholds [9]. However, there is a relative paucity of literature on taVNS treatment of chronic pain. To our knowledge, this is the first intervention study with the aim of modulating vagus nerve activity as a treatment method for women with PDM. Our study confirmed the effectiveness and evaluated the durability of taVNS therapy on PDM by proving improvement in dysmenorrhea symptoms. Thus, taVNS might be considered an option for adjunctive treatment in relieving menstrual pain. Women with PDM are often associated with psychological distress and negative emotions, which may in turn amplify and maintain the pain state [10]. Our findings showed that individual-level changes in CMSS scores following taVNS were positively correlated with pain-related fear, anxiety, and catastrophizing. We speculated that taVNS may reduce the affective component of menstrual pain by improving pain-related emotions. In conclusion, the present findings suggest that taVNS has the potential to provide a non-pharmacologic treatment option for PDM. Meanwhile, considering that taVNS is non-invasive, safe, and convenient, it may provide a device-based home method for PDM, which would be a potential clinical solution for a larger PDM population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vagus Nerve StimulationTranscutaneous Electric Nerve StimulationFemaleHumansPilot ProjectsDysmenorrheaVagus Nerve

Autor:innen und Institutionen

  • Center for Brain Imaging, School of Life Science and Technology, Xidian University, Xi'an, 710126, PR China; Engineering Research Center of Molecular & Neuroimaging, Ministry of Education, Xi'an, 710126, PR China.
  • First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China. Electronic address: wanghuandun@163.com.
  • First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China. Electronic address: zmmri@163.com.
  • Center for Brain Imaging, School of Life Science and Technology, Xidian University, Xi'an, 710126, PR China; Engineering Research Center of Molecular & Neuroimaging, Ministry of Education, Xi'an, 710126, PR China. Elect…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, C., Su, W., Feng, X., Qi, X., Hong, Z., Dun, W., Zhang, M., & Liu, J. (2023). Transcutaneous auricular vagus nerve stimulation for the treatment of primary dysmenorrhea: A pilot study. Brain Stimulation. https://doi.org/10.1016/j.brs.2023.04.010

Vancouver

Wang C, Su W, Feng X, Qi X, Hong Z, Dun W, et al. Transcutaneous auricular vagus nerve stimulation for the treatment of primary dysmenorrhea: A pilot study. Brain Stimulation. 2023. doi:10.1016/j.brs.2023.04.010

BibTeX
@article{Wang2023,
  author = {Wang, Chenxi and Su, Wenjie and Feng, Xinyue and Qi, Xingang and Hong, Zilong and Dun, Wanghuan and Zhang, Ming and Liu, Jixin},
  title = {Transcutaneous auricular vagus nerve stimulation for the treatment of primary dysmenorrhea: A pilot study},
  journal = {Brain Stimulation},
  year = {2023},
  doi = {10.1016/j.brs.2023.04.010}
}
Kostenlos starten →